BuSpar Patent Listed By FDA Following Amended Declaration By Bristol
Executive Summary
FDA's listing of an additional patent on buspirone in the "Orange Book" reflects Bristol's amended declaration that the patent "covers the use of the approved product" BuSpar, FDA said in a Dec. 6 letter to the company.